Literature DB >> 26620828

Erratum to: Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.

Guilan Quan1, Xin Pan2, Zhouhua Wang3, Qiaoli Wu4, Ge Li5, Linghui Dian6, Bao Chen7, Chuanbin Wu8.   

Abstract

Entities:  

Year:  2015        PMID: 26620828      PMCID: PMC4666079          DOI: 10.1186/s12951-015-0104-6

Source DB:  PubMed          Journal:  J Nanobiotechnology        ISSN: 1477-3155            Impact factor:   10.435


× No keyword cloud information.

Erratum to: J Nanobiotechnol DOI 10.1186/s12951-015-0068-6

Panel A, B, and C from Figure 7 (Fig. 1 here) of this work [1] was generated using HepG2, SMMC7721, and NIH 3T3 cells, respectively. After publication of this work, we noted that they were inadvertently labelled as NIH 3T3, HepG2 and SMMC7721 cells. The figure caption of Figure 7 has now been corrected in this erratum.
Figure 1

Flow cytometry study. ASGPR-positive cells HepG2 (A) and SMMC7721 (B), and ASGPR-negative cells NIH 3T3 (C) incubated with blank medium (control), Lac-MSNs, MSNs, and excess free lactose with Lac-MSNs for 4 h at 37°C. Data represent mean ± SD (n = 3).

Flow cytometry study. ASGPR-positive cells HepG2 (A) and SMMC7721 (B), and ASGPR-negative cells NIH 3T3 (C) incubated with blank medium (control), Lac-MSNs, MSNs, and excess free lactose with Lac-MSNs for 4 h at 37°C. Data represent mean ± SD (n = 3).
  1 in total

1.  Lactosaminated mesoporous silica nanoparticles for asialoglycoprotein receptor targeted anticancer drug delivery.

Authors:  Guilan Quan; Xin Pan; Zhouhua Wang; Qiaoli Wu; Ge Li; Linghui Dian; Bao Chen; Chuanbin Wu
Journal:  J Nanobiotechnology       Date:  2015-02-03       Impact factor: 10.435

  1 in total
  1 in total

Review 1.  Recent progress in drug delivery.

Authors:  Chong Li; Jiancheng Wang; Yiguang Wang; Huile Gao; Gang Wei; Yongzhuo Huang; Haijun Yu; Yong Gan; Yongjun Wang; Lin Mei; Huabing Chen; Haiyan Hu; Zhiping Zhang; Yiguang Jin
Journal:  Acta Pharm Sin B       Date:  2019-08-19       Impact factor: 11.413

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.